Abstract 500P
Background
With the advances of next-generation sequencing (NGS), compound EGFR mutations were more frequently observed. Prior studies reported that patients with compound EGFR mutations showed poor clinical outcome. However, molecular and clinical features of NSCLC patients harboring such mutations were poorly investigated.
Methods
A total of 1091 primary NSCLC patients were enrolled. Variants of EGFR and other driver genes were analyzed by NGS. EGFR exon 19 deletion (19 del) and L858R mutations were defined as common sensitizing mutations; EGFR G719S/C/A mutations were defined as uncommon sensitizing mutations; other mutations were defined as rare mutations. Patients were divided as follows: common sensitizing and rare mutations (group A); uncommon sensitizing and rare mutations (group B); double rare mutations (group C).
Results
Overall, EGFR mutations were detected in 418 patients (38.3%), and 76 cases (7.0%) carried compound EGFR mutations. Frequencies of group A, B and C were 76.3%, 18.4% and 5.3%, respectively, indicating compound mutations mainly consist of sensitizing and atypical mutations. Compound mutations were more frequently observed in young patients (p = 0.017), and distributions of the three groups were different between early and adavanced stages (p = 0.032). According to types of common sensitizing mutations, rate of compound mutations harboring EGFR L858R alteration was strikingly higher than that carrying EGFR 19 del alteration (p = 0.039). Further analysis demonstrated that frequency of EGFR T790M mutation among the three groups showed significant difference (p = 0.031). Genomic data revealed TP53 mutations markedly coexisted with compound mutations compared with single mutation (p = 0.03). Moreover, relative EGFR mutant allele frequency (rMAF) of group A, calculated as MAF of EGFR sensitizing mutations / MAF of EGFR rare mutations, was higher than that of group B (p = 0.007).
Conclusions
This study comprehensively explored the population characteristics of compound EGFR mutations from a large cohort of primary NSCLC patients, which will be helpful to guide personalized therapy and promote the clinical management of this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Cheng: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. H. Wang: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. F. Lou: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. S. Cao: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract